Appointments and advancements for June 2, 2026

Endpoints NewsTravere pays Everest $112M upfront to grow rare kidney disease pipeline

Endpoints NewsLegend Biotech shares first in vivo CAR-T data, its next act after Carvykti

FierceBiotechFulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

FierceBiotechASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push

PharmaVoiceAs amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next

LabiotechThe biggest biotech funding rounds in May 2026

BioWorldOther news to note for June 2, 2026

FierceBiotechASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice

FierceBiotechASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray

FierceBiotechMindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs

BioPharma DiveAbiVax falls as safety worries cloud ‘landmark’ immune drug results

Endpoints News#ASCO26: Celcuity plans another FDA filing after positive breast cancer readout